
Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Date | Quarter | Revenue Forecast | Actual Revenue | Reported EPS | Consensus EPS | Beat/Miss |
---|---|---|---|---|---|---|
09/30/2025 | Q3 | $12.2M | -- | -- | -$1.31 | -- |
08/05/2025 | Q2 | $6.4M | -- | -- | -$1.40 | -- |
05/06/2025 | Q1 | $6M | -- | -$1.58 | -$1.28 | -$0.30 |
02/11/2025 | Q4 | $7.3M | $35M | -$0.44 | -$1.19 | $0.75 |
11/05/2024 | Q3 | $7.1M | -- | -$1.01 | -$1.40 | $0.39 |
08/05/2024 | Q2 | $13.6M | -- | -$1.49 | -$1.42 | -$0.07 |
05/08/2024 | Q1 | $26.5M | -- | -$1.43 | -$1.46 | $0.03 |
02/21/2024 | Q4 | $123.1M | $200M | $1.13 | $0.05 | $1.08 |
11/06/2023 | Q3 | -- | -- | -$1.41 | -$1.95 | $0.54 |
08/07/2023 | Q2 | -- | -- | -$0.98 | -$2.10 | $1.12 |
05/08/2023 | Q1 | -- | -- | -$0.67 | -$1.64 | $0.97 |
02/21/2023 | Q4 | -- | -- | -$1.41 | -$2.27 | $0.86 |
11/01/2022 | Q3 | -- | -- | -$2.24 | -$2.24 | -$0.00 |
08/08/2022 | Q2 | -- | -- | -$2.40 | -$2.21 | -$0.19 |
05/09/2022 | Q1 | -- | -- | -$2.32 | -$1.97 | -$0.35 |
02/16/2022 | Q4 | -- | -- | -$1.84 | -$1.78 | -$0.06 |
11/03/2021 | Q3 | -- | -- | -$1.67 | -$1.76 | $0.09 |
07/29/2021 | Q2 | -- | -- | $9.44 | $3.12 | $6.32 |
04/27/2021 | Q1 | -- | -- | -$1.51 | -$1.47 | -$0.04 |
02/16/2021 | Q4 | -- | -- | -$1.52 | -$1.28 | -$0.24 |
10/28/2020 | Q3 | -- | -- | -$1.32 | -$1.19 | -$0.13 |
07/27/2020 | Q2 | -- | -- | -$1.30 | -$0.99 | -$0.31 |
04/28/2020 | Q1 | -- | -- | -$1.15 | -$1.04 | -$0.11 |
02/12/2020 | Q4 | -- | -- | $0.51 | $0.05 | $0.46 |
10/28/2019 | Q3 | -- | -- | $2.40 | $1.79 | $0.61 |
07/29/2019 | Q2 | -- | -- | -$1.01 | -$0.90 | -$0.11 |
04/29/2019 | Q1 | -- | -- | -$0.93 | -$0.90 | -$0.03 |
02/25/2019 | Q4 | -- | -- | -$0.92 | -- | -- |
11/07/2018 | Q3 | -- | -- | -$1.07 | -- | -- |
08/07/2018 | Q2 | -- | -- | -$0.82 | -- | -- |
05/08/2018 | Q1 | -- | -- | -$0.62 | -- | -- |
03/08/2018 | Q4 | -- | -- | $0.01 | -- | -- |
11/08/2017 | Q3 | -- | -- | -$0.62 | -- | -- |
08/10/2017 | Q2 | -- | -- | -$0.56 | -- | -- |
03/31/2017 | Q1 | -- | -- | -$0.54 | -- | -- |
12/31/2016 | Q4 | -- | -- | $0.43 | -- | -- |
09/30/2016 | Q3 | -- | -- | -$0.37 | -- | -- |
06/30/2016 | Q2 | -- | -- | -$0.43 | -- | -- |
03/31/2016 | Q1 | -- | -- | -$0.29 | -- | -- |
12/31/2015 | Q4 | -- | -- | -$0.42 | -- | -- |
09/30/2015 | Q3 | -- | -- | -$0.22 | -- | -- |
CRISPR Therapeutics AG reported -- worth of top line sales in its most recent quarter.
CRISPR Therapeutics AG announced earnings per share of -$1.58 which represents a miss of analyst forecast a -$1.28 per share.
CRISPR Therapeutics AG reported -$57.5M that represents -$0.67 per share over the last quarter.
CRISPR Therapeutics AG's earnings are forecast to decrease from -$4.34 per share to -$5.12 per share next year representing a decrease of -23.5%.
CRISPR Therapeutics AG's next earnings date is August 5, 2025.
Signup to receive the latest stock alerts
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Market Cap: $4.2T
P/E Ratio: 58x
Market Cap: $3.8T
P/E Ratio: 43x
Market Cap: $3.1T
P/E Ratio: 35x
SharpLink Gaming [SBET] is down 2.6% over the past day.
Exodus Movement [EXOD] is down 4.14% over the past day.
Unity Software [U] is up 7.51% over the past day.